

# DEARBORN PARTNERS

---

Another Dearborn Partners Core Rising and High & Rising Dividend SMA Portfolio Increase: Gilead Sciences, Inc.

On February 1, 2022, Gilead Sciences, Inc. (GILD) announced a 2.8% increase in its quarterly dividend per share to \$0.73 (\$2.92 annually) from \$0.71 (\$2.84 annually). The cash dividend will be paid on March 30, 2022 to holders of record as of March 15, 2022. This is the 7<sup>th</sup> consecutive annual increase in the dividend paid by Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead Sciences, Inc. is in the Health Care sector of both of our Dearborn Partners Rising Dividend separately managed account (SMA) portfolios. So far this year, 6 of 49 companies in our Core Rising Dividend portfolio have announced 6 dividend increases averaging about 19.8% more than these companies paid a year earlier. In our High & Rising Dividend Portfolio, 3 of 25 companies have announced 3 dividend increases averaging about 3.6% more than these companies paid a year earlier. No companies in these portfolios have reduced or suspended dividends so far this year.

Thank you for your continued interest in our Dearborn Partners Rising Dividend Strategy.

*This dividend increase announcement is not a complete description of, nor a recommendation to invest in, any investment strategy (the "Strategy") mentioned herein. It is for informational purposes only and does not constitute an offer to sell nor a solicitation to buy, is not a recommendation regarding any securities transaction, nor is it an offer to provide advisory or other services by Dearborn Partners, L.L.C. The information contained in this writing should not be construed as financial or investment advice on any subject matter. Past performance is no guarantee of future results. There is no assurance the Strategy will be profitable, achieve its objectives, be suitable for you, or not incur losses. Some of the information herein has been obtained from third party sources. We believe such information is reliable but we have not in each case verified its accuracy or completeness. Any opinions herein are as of the date of this report and are subject to change without notice. Dividends are not guaranteed and must be authorized by the company's board of directors. There is no assurance that any Rising Dividend portfolio company will increase its dividend, or not reduce its dividend, or not have a significant decrease in its stock price. Dividend yield is one component of performance and should not be the only consideration for investment. Dearborn Partners L.L.C. is an investment adviser registered under the Investment Advisers Act of 1940, as amended. Registration does not imply a certain level of skill or training. For a complete list of all Dearborn Rising Dividend holdings that in the past year - increased their dividends, had no dividend increases, or had a dividend decrease, please contact the Dearborn Rising Dividend Team at [RD@dearbornpartners.com](mailto:RD@dearbornpartners.com). It should not be assumed that portfolio trades made in the future will be profitable, or will increase their dividends, or will equal the performance of the securities in this announcement.*